Table 1.
Participants’ demographics and medical characteristics by group and overall at baseline (N = 177)
| Variable | StanCBT-I (N = 59) |
StepCBT-I (N = 118) |
Overall (N =177) |
Test (chi-square or t-test) |
|---|---|---|---|---|
| Age (years)—M (SD) | 54.8(11.1) | 55.5(10.0) | 55.2(10.4) | 0.18, p = .68 |
| Sex—% women (n) | 82.8(48) | 88.0(103) | 86.3(151) | 0.87, p = .34 |
| Education—% with at least college degree (n) | 87.9(51) | 89.0(105) | 88.6(156) | 0.04, p = .84 |
| Marital status—% married/common law (n) | 70.7(41) | 63.3(74) | 65.7(115) | 0.95, p = .33 |
| Family income—% (n) | 3.79, p = .43 | |||
| 0–39 K$ | 11.9(7) | 18.6(22) | 16.4 (29) | |
| 40–79K$ | 33.9(20) | 39.8(47) | 37.9(67) | |
| 80–119K$ | 22.0(13) | 21.2(25) | 21.5(38) | |
| 120K$ or more | 22.0(13) | 14.4(17) | 16.9(30) | |
| No answer | 10.2(6) | 5.9(7) | 7.3(13) | |
| Occupation—% (n) | 2.36, p = .50 | |||
| Working full/part time | 8.5(5) | 16.9(20) | 14.1(25) | |
| Sick leave | 54.2(32) | 48.3(57) | 50.3(89) | |
| Retirement | 30.5(18) | 28.0(33) | 28.8(51) | |
| Other | 6.8(4) | 6.8(8) | 6.8(12) | |
| Medical comorbidity—% (n) | 69.0(40) | 69.5(82) | 69.3(122) | 0.01, p = .94 |
| Psychotropic medication usage—% (n) | 47.5(28) | 46.6(55) | 46.9(83) | 0.01, p = .92 |
| Time since cancer diagnosis (months)—M (SD) | 7.9(3.5) | 9.7(11.2) | 9.2(9.5) | 1.54, p = .24 |
| Cancer diagnosis—% (n) | 4.47 (df = 3), p = .22 | |||
| Breast | 72.4(42) | 78.8(93) | 76.7(135) | |
| Prostate | 8.6(5) | 5.1(6) | 6.3(11) | |
| Gynecological | 8.6(5) | 2.5(3) | 4.6(8) | |
| Other | 10.3(6) | 13.6(16) | 12.5(22) | |
| Cancer stage—% (n) | 10.32 (df = 5), p = .07 | |||
| 0 | 8.5 (5) | 4.2 (5) | 5.7 (10) | |
| I | 15.3 (9) | 17.8 (21) | 17.0 (30) | |
| II | 1.7 (1) | 13.6 (16) | 9.6 (17) | |
| III | 6.8 (4) | 2.5 (3) | 4.0 (7) | |
| IV | 0.0 (0) | 1.7 (2)† | 1.1 (2)† | |
| Unkown/not available | 67.8 (40) | 60.2 (71) | 62.7 (111) | |
| Cancer treatments–% (n)* | ||||
| Surgery | 83.1(49) | 90.6(106) | 88.1(155) | 2.13, p = .14 |
| Chemotherapy | 55.9(33) | 48.7(57) | 51.1(90) | 0.82, p = .37 |
| Radiotherapy | 84.8(50) | 90.6(106) | 88.6(156) | 1.33, p = .25 |
| Hormone therapy | 42.4(25) | 52.1(61) | 48.9(86) | 1.50, p = .22 |
*All participants had completed their radiation therapy at study entry. Only three patients treated with chemotherapy were still on treatment at study entry. For hormone therapy, 74% of the 86 patients treated were still on treatment at study entry and this percentage was not significantly different between groups (63.2% for StanCBT-I vs. 78.2% for StepCBT-I), χ2 (1) = 1.67, p = .20.
†These patients were included because their cancers were stages IVA and had spread to lymph nodes only.